Market closed

Incyte/$INCY

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Incyte

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Ticker

$INCY

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Wilmington, United States

Employees

2,524

Website

www.incyte.com

Incyte Metrics

BasicAdvanced

$14B

487.70 $0.15

0.73 -

Price and volume

Market cap

$14B

Beta

0.73

52-week high

$82.15

52-week low

$50.35

Average daily volume

1.8M

Financial strength

Current ratio

1.983

Quick ratio

1.598

Long term debt to equity

0.89

Total debt to equity

1.151

Interest coverage (TTM)

-5.59%

Management effectiveness

Return on assets (TTM)

-0.12%

Return on equity (TTM)

0.80%

Valuation

Price to earnings (TTM)

487.701

Price to revenue (TTM)

3.815

Price to book

4.4

Price to tangible book (TTM)

4.82

Price to free cash flow (TTM)

925.542

Growth

Revenue change (TTM)

12.94%

Earnings per share change (TTM)

-92.12%

3-year revenue growth (CAGR)

11.85%

3-year earnings per share growth (CAGR)

-60.52%

What the Analysts think about Incyte

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Incyte stock.

Incyte Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Incyte Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Incyte News

AllArticlesVideos

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

Seeking Alpha·1 day ago

Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire·2 days ago

Incyte: Multiple Drug Launches Bode Well For Future Growth

Seeking Alpha·4 days ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $INCY

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Incyte stock?

Incyte (INCY) has a market cap of $14B as of January 15, 2025.

What is the P/E ratio for Incyte stock?

The price to earnings (P/E) ratio for Incyte (INCY) stock is 487.7 as of January 15, 2025.

Does Incyte stock pay dividends?

No, Incyte (INCY) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Incyte dividend payment date?

Incyte (INCY) stock does not pay dividends to its shareholders.

What is the beta indicator for Incyte?

Incyte (INCY) has a beta rating of 0.73. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.